Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

Or‐Yam Revach, Angelina M. Cicerchia, Ofir Shorer, Boryana Petrova, Seth Anderson, Joshua Park, Lee Chen, Arnav Mehta, Samuel J. Wright, Niamh McNamee, Aya Tal-Mason, Giulia Cattaneo, Payal Tiwari, Hongyan Xie, Johanna M. Sweere, Li-Chun Cheng, Natalia Sigal, Elizabeth Enrico, Marisa Miljkovic, Shane A. Evans, Ngan Luu-Thuy Nguyen, Mark Whidden, Ramji Srinivasan, Matthew H. Spitzer, Yi Sun, Tatyana Sharova, Aleigha Lawless, William A. Michaud, Martin Q. Rasmussen, Jacy Fang, Claire A. Palin, Feng Chen, Xinhui Wang, Cristina R. Ferrone, Donald P. Lawrence, Ryan J. Sullivan, David Liu, Uma M. Sachdeva, Debattama R. Sen, Keith T. Flaherty, Robert T. Manguso, Lloyd Bod, Manolis Kellis, Genevieve M. Boland, Keren Yizhak, Jiekun Yang, Naama Kanarek, Moshe Sade-Feldman, Nir Hacohen, Russell W. JenkinsbioRxiv 2024 · DOI

TL;DR

This paper reveals that the ecto-enzyme CD38 drives T cell exhaustion, a major cause of resistance to cancer immunotherapy. By blocking CD38, researchers restored T cell function and sensitivity to immunotherapy in preclinical models, offering a promising new therapeutic strategy.

What Problem Does This Paper Address?

Cancer immunotherapy, particularly immune checkpoint blockade (ICB), has revolutionized cancer treatment, but a significant challenge remains: resistance. Approximately 50% of patients with metastatic melanoma do not respond to ICB, and many who initially respond eventually develop resistance. A key driver of this resistance is T cell exhaustion, a state where T cells become dysfunctional due to chronic exposure to tumor antigens within the tumor microenvironment. The paper investigates the role of CD38, an enzyme involved in NAD+ metabolism, in this process and explores its potential as a therapeutic target to overcome ICB resistance.

Methods

The researchers employed a multi-pronged approach:

  • Single-cell RNA sequencing (scRNAseq): This was used to analyze immune cells from melanoma patients treated with ICB, identifying distinct T cell clusters and their gene expression profiles.
  • CyTOF (Cytometry by Time-of-Flight): This technique allowed for high-dimensional analysis of immune cells in peripheral blood to assess CD38 expression and its correlation with ICB response.
  • Organotypic Tumor Spheroids (PDOTS/MDOTS): These 3D culture models, derived from patient tumors or murine models, mimic the tumor microenvironment and allow for ex vivo testing of therapeutic interventions.
  • CRISPR/Cas9 Gene Editing: Used to genetically delete CD38 in CAR-T cells to assess its necessity for T cell dysfunction.
  • Metabolomic Profiling (LC-MS): This was employed to analyze intracellular and extracellular metabolites, particularly focusing on NAD+ and related pathways, to understand the metabolic consequences of CD38 targeting.
  • Mitochondrial Function Assays: Assessed mitochondrial mass, membrane potential, oxygen consumption rate (OCR), and extracellular acidification rate (ECAR) to evaluate the impact of CD38 on T cell bioenergetics.

Datasets

The study utilized several datasets:

  • Published scRNAseq data: From melanoma patients treated with ICB (n=10) and non-small cell lung cancer (NSCLC) patients (n=18).
  • Patient-derived organotypic tumor spheroids (PDOTS): From melanoma patients with varying responses to ICB.
  • Murine tumor models: B16-ova and CT26-GFP tumors were used to generate murine-derived organotypic tumor spheroids (MDOTS).
  • Human B7-H3-directed chimeric antigen receptor T-cells (B7-H3.CAR-T): Used for in vitro studies of T cell dysfunction and the effects of CD38 manipulation.

Key Insights and Ideas

  • CD38 as a marker and driver of T cell exhaustion: The study strongly links high CD38 expression in CD8+ T cells to T cell exhaustion and resistance to ICB. This suggests CD38 isn't just a bystander but actively contributes to the dysfunctional state.
  • The CD38-NAD+ axis is crucial for T cell function: Disrupting CD38 activity restored cellular NAD+ pools, which in turn improved mitochondrial function, proliferation, and effector functions of T cells. This highlights the critical role of NAD+ metabolism in maintaining T cell health and anti-tumor activity.
  • CD38 blockade can overcome ICB resistance: Combining CD38 blockade with ICB therapies showed significant anti-tumor effects in both human and murine models, particularly in ICB-resistant settings. This offers a tangible therapeutic avenue.
  • CD38's impact extends beyond NAD+: While NAD+ restoration is key, the study also hints at CD38's role in promoting immune suppression via adenosine, suggesting a multi-faceted mechanism of action.

Key Results

  • CD38+CD8+ T cells are enriched in ICB-resistant melanoma patients and exhibit hallmarks of exhaustion (low TCF7, impaired proliferation, reduced effector function, altered bioenergetics).
  • CD38 expression on CD8+ T cells is a strong predictor of ICB resistance (AUC 0.87 in melanoma, AUC 0.75 in NSCLC).
  • Genetic deletion or pharmacological inhibition of CD38 in T cells restored their function and sensitivity to ICB in both murine and patient-derived ex vivo models.
  • Dual PD-1/CD38 blockade demonstrated superior anti-tumor activity compared to single-agent therapies in PDOTS, with a 56.7% response rate in ICB-resistant melanoma patients.
  • CD38 inhibition restored cellular NAD+ pools and improved mitochondrial function, leading to enhanced T cell fitness.

Limitations and Future Work

  • Mechanism of CD38 regulation: The precise molecular mechanisms by which CD38 is transcriptionally regulated during chronic antigen exposure and T cell exhaustion remain unclear. Further investigation is needed to understand the factors governing its upregulation and downregulation.
  • Reversibility of CD38 expression: The extent to which CD38-driven exhaustion is reversible requires further study.
  • Role of other ectoenzymes: The study notes that other ectoenzymes might compensate for CD38 inhibition, suggesting that a deeper understanding of these compensatory mechanisms could be beneficial.
  • Clinical translation: While promising, the findings are based on preclinical and ex vivo models. The authors highlight that CD38 monoclonal antibodies are already FDA-approved for other indications, providing a clear path for rapid translation to clinical trials for ICB resistance. Future work will focus on clinical trials to validate these findings in human patients.

Summary updated

Abstract

A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma<sup>1,2</sup>. T cell exhaustion, resulting from chronic antigen exposure in the tumour microenvironment, is a major driver of ICB resistance<sup>3</sup>. Here, we show that CD38, an ecto-enzyme involved in nicotinamide adenine dinucleotide (NAD<sup>+</sup>) catabolism, is highly expressed in exhausted CD8<sup>+</sup> T cells in melanoma and is associated with ICB resistance. Tumour-derived CD38<sup>hi</sup>CD8<sup>+</sup> T cells are dysfunctional, characterised by impaired proliferative capacity, effector function, and dysregulated mitochondrial bioenergetics. Genetic and pharmacological blockade of CD38 in murine and patient-derived organotypic tumour models (MDOTS/PDOTS) enhanced tumour immunity and overcame ICB resistance. Mechanistically, disrupting CD38 activity in T cells restored cellular NAD<sup>+</sup> pools, improved mitochondrial function, increased proliferation, augmented effector function, and restored ICB sensitivity. Taken together, these data demonstrate a role for the CD38-NAD<sup>+</sup> axis in promoting T cell exhaustion and ICB resistance, and establish the efficacy of CD38 directed therapeutic strategies to overcome ICB resistance using clinically relevant, patient-derived 3D tumour models.
BibTeX
@misc{revach2024disrupting,
  author = {Or‐Yam Revach and Angelina M. Cicerchia and Ofir Shorer and Boryana Petrova and Seth Anderson and Joshua Park and Lee Chen and Arnav Mehta and Samuel J. Wright and Niamh McNamee and Aya Tal-Mason and Giulia Cattaneo and Payal Tiwari and Hongyan Xie and Johanna M. Sweere and Li-Chun Cheng and Natalia Sigal and Elizabeth Enrico and Marisa Miljkovic and Shane A. Evans and Ngan Luu-Thuy Nguyen and Mark Whidden and Ramji Srinivasan and Matthew H. Spitzer and Yi Sun and Tatyana Sharova and Aleigha Lawless and William A. Michaud and Martin Q. Rasmussen and Jacy Fang and Claire A. Palin and Feng Chen and Xinhui Wang and Cristina R. Ferrone and Donald P. Lawrence and Ryan J. Sullivan and David Liu and Uma M. Sachdeva and Debattama R. Sen and Keith T. Flaherty and Robert T. Manguso and Lloyd Bod and Manolis Kellis and Genevieve M. Boland and Keren Yizhak and Jiekun Yang and Naama Kanarek and Moshe Sade-Feldman and Nir Hacohen and Russell W. Jenkins},
  title = {{Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy}},
  year = {2024},
  doi = {10.1101/2024.02.12.579184},
  howpublished = {bioRxiv},
}
Figure